

Abbvie Inc (ABBV.K)

	Market Data
Last Close	103.28
Price 52 Week High	109.15
Price 52 Week Low	62.55
Market Cap (M)	\$182,302.84
Enterprise Value (M)	\$261,430.84

	Wall St. Recos
Strong Buy	6
Buy	11
Hold	5
Sell	0
Sell	0

	Price Targets
Price Target - Mean	115.71
Price Target - Number of Included Estimates	21
Price Target - High	135
Price Target - Low	97
Price Target - Standard Deviation	10.55
Long Term Growth - Mean	10.97
Lido Estimate	121
Upside	17.16

Multiples	LTM	NTM
EV/SALES	6.43	6.43
EV/EBITDA	15.71	15.71
EV/EBIT	22.29	22.29
P/E	22.58	22.58
P/B	11.94	11.94
ROA (%)	7.06	7.06
ROE (%)	209.57	209.57
PEG	2.06	2.06

Key Points

Recent move is due to the positive data on their two new drugs Rinovoq and Skyrizi. Rinovoq is for ulcerative colitis and Skyrizi is for Psoriasis.

Positive news for the street because there is another revenue stream after Humira, which is supposed to go off patent in 2022.

These drugs are expected to have 11 billion in sales combined by 2025.

The issue with ABBV is their debt and the growth by acquisition strategy. Despite the acquisitions there wasn't much clarity on what was going to replace Humira. There is some light at the end of that tunnel now.